Transitional Growth Hormone (GH) Use in Growth Hormone Deficient (GHD) Cancer Survivors

Launched by THE LEEDS TEACHING HOSPITALS NHS TRUST · Dec 14, 2015

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 16--22 years inclusive.
• • Both genders.
• • Able to provide informed consent.
• • Severe GH deficiency (peak GH\<5mcg/l on stimulation).
• • No GH replacement therapy during the three months preceding the baseline visit.
• • Stable anterior pituitary hormone (i.e. sex steroids, hydrocortisone, thyroxine) therapy over the previous six months.
• • Life expectancy \>24 months.
• Exclusion Criteria:
• • Acute critical illness (Patients suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure, or similar conditions).
• • Active malignant disease (i.e. undergoing active treatment or palliation).
• • Patients treated for an intracranial malignancy should have completed therapy two years prior to entering the study.
• • Active Cushing's disese or acromegaly
• • Pregnancy or desire to conceive within the following year. Patients at risk of pregnancy will be screened by urine pregnancy (HCG) test at the baseline evaluation \& treatment initiation visit.
• • Breast feeding.
• • Proliferative diabetic retinopathy.
• • Sensitivity to GH or its preservative